This page is reference information only. Most compounds described here are research chemicals, not FDA-approved medications. MyTRT does not sell, recommend, or endorse the use of these substances. Always consult a qualified physician.
Cagrisema Sodium
Peptide Compound for Metabolic Research
/WHAT_IT_IS
Cagrisema is a co-formulation of cagrilintide and semaglutide, combining the effects of amylin and GLP-1 receptor agonism for enhanced weight loss and glycemic control.
/USAGE
Used in research on obesity, appetite regulation, and glucose metabolism. Promising results in weight loss and Type 2 diabetes models.
/MECHANISM_OF_ACTION
Combines GLP-1 receptor activation with amylin receptor activity to suppress appetite, slow gastric emptying, and improve metabolic parameters.
Reported Benefits
- +Appetite suppression
- +Weight reduction
- +Improved glucose control
- +Delayed gastric emptying
Reported Side Effects
- −Nausea
- −Constipation
- −Loss of appetite
- −Mild gastrointestinal discomfort
/STACKED_WITH
/RESEARCH_NOTES
Emerging as a dual-action therapy in metabolic research. Combination shows stronger efficacy than monotherapy.
/REFERENCE
https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915082&utm_source=chatgpt.com/RELATED
Browse all 89 in the app.
MyTRT's in-app library has the same 89 peptide entries plus dosing notes, stack builders, and the ability to log them alongside your TRT protocol.